Market Research Logo

Intravenous Immunoglobulin (IVIG) Market by Application (Hypogammaglobulinemia, Chronic Inflammatory Demyelinating Polyneuropathy, Immunodeficiency Diseases, Myasthenia Gravis, Multifocal Motor Neuropathy, Idiopathic Thrombocytopenic Purpura, Inflammatory

Intravenous Immunoglobulin (IVIG) Market by Application (Hypogammaglobulinemia, Chronic Inflammatory Demyelinating Polyneuropathy, Immunodeficiency Diseases, Myasthenia Gravis, Multifocal Motor Neuropathy, Idiopathic Thrombocytopenic Purpura, Inflammatory Myopathies, Specific Antibody Deficiency, Guillain-Barre syndrome, and Others) and Type (IgG, IgA, IgM, IgE, and IgD): Global Opportunity Analysis and Industry Forecast, 2018 - 2025

Intravenous Immunoglobulin Market Overview:

The global intravenous immunoglobulin (IGIV) market was valued at $8,995 million in 2017and is projected to reach $15,964 million by 2025, registering a CAGR of 7.5% from 2018 to 2025.

Immunoglobulins (IGs), also referred to as antibodies, are glycoproteins produced by the blood plasma in response to foreign bodies or antigens. They are highly complex entities and are specific in their action. These immunoglobulins are obtained from blood through the process of fractionation and are purified for use in therapeutic and nontherapeutic areas.

Increase in prevalence of immunodeficiency and autoimmune diseases such as chronic inflammatory demyelinating polyneuropathy, hypogammaglobulinemia, & others and rise in adoption of immunoglobulin therapies for the treatment of various autoimmune disorders majorly drive the growth of the IVIG market. Furthermore, increase in approval of IVIG drugs from the Food and Drug Administration (FDA), European Medicine Agency (EMA), and other government agencies is expected to accelerate the growth of the IVIG industry. However, stringent government regulations toward the vigorous use of immunoglobulins, inflated cost of therapy, and high risk of side effects associated with the use of immunoglobulin intravenously are anticipated to hamper the market growth. On the contrary, significant investment in healthcare sector is expected to provide lucrative opportunities for the market growth in the near future.

The global intravenous immunoglobulin (IVIG) market is characterized based on application, type, and region. By application, the market is segmented into hypogammaglobulinemia, CIDP, immunodeficiency diseases, myasthenia gravis, multifocal motor neuropathy, idiopathic thrombocytopenic purpura (ITP), inflammatory myopathies, specific antibody deficiency, Guillain€“Barre syndrome, and others. Depending on type, it is classified into IgG, IgA, IgM, IgE, and IgD. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Key Benefits for Intravenous Immunoglobulin Market:

The report provides an in-depth analysis of the intravenous immunoglobulin market along with the current trends and future estimations to elucidate the imminent investment pockets.
A comprehensive analysis of the factors that drive and restrict the market growth is provided in this study.
The report provides a detailed quantitative analysis of the industry from 2018 to 2025 to assist stakeholders to capitalize on the prevailing market opportunities.
An extensive analysis of the key segments of the industry helps to understand the trends in the intravenous immunoglobulin market globally.
Key players and their strategies are provided to understand the competitive outlook of the industry.

Intravenous Immunoglobulin Key Market Segments:

By Application

Hypogammaglobulinemia
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Primary Immunodeficiency Disease
Myasthenia Gravis
Multifocal Motor Neuropathy
Idiopathic Thrombocytopenic Purpura (ITP)
Inflammatory Myopathies
Specific Antibody Deficiency
Guillain€“Barre Syndrome
Others

By Type

IgG
IgA
IgM
IgE
IgD

By Region

North America
U.S.
Canada
Mexico
Europe
UK
France
Germany
Italy
France
Austria
Russia
Rest of Europe
Asia-Pacific
Japan
China
India
Australia
Rest of Asia-Pacific
LAMEA
Brazil
Argentina
Turkey
Saudi Arabia
Rest of LAMEA

Key players Profiled
Baxter international Inc.
CSL Ltd.
Grifols, S.A.
Octapharma AG
Kedrion Biopharma Inc.
LFB Group
Biotest AG
China Biologics Products, Inc.
Takeda Pharmaceuticals
Bayer AG

The other players of the intravenous immunoglobulin market included in the value chain analysis (but not profiled in the report) are as follows:

Hualan Biological Engineering Inc.
Omrix Biopharmaceuticals Ltd.
Behring GmbH
Shanghai RAAS Blood Products Co., Ltd.
Option Care Enterprises, Inc.
ADMA Biologics, Inc.
BioScrip, Inc.


CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key benefits for stakeholders
1.3. Key market segments
1.4. Research methodology
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools & models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Overview of Immunoglobulin
3.2.1. Patented products
3.2.2. Epidemiology and economic burden of chronic conditions
3.3. Key findings
3.3.1. Top Investment Pockets
3.4. Porters five forces analysis
3.5. Value chain analysis
3.5.1. Primary activities
3.5.2. Support activities
3.6. Market share analysis, 2017
3.7. Product scenario in intravenous immunoglobulin market
3.8. Government regulations and reimbursements
3.8.1. U.S.
3.8.2. Europe
3.8.3. France
3.8.4. Germany
3.8.5. Italy
3.8.6. China
3.8.7. Japan
3.8.8. India
3.9. Indications for immunoglobulin
3.9.1. U.S. FDA indications
3.9.2. EMA
3.10. Component analysis of immunoglobulin G (IgG)
3.10.1. IgG1
3.10.2. IgG2
3.10.3. IgG3
3.10.4. IgG4
3.11. Market dynamics
3.11.1. Drivers
3.11.1.1. Rise in prevalence of immunodeficiency diseases
3.11.1.2. Increase in adoption of immunoglobulin treatment
3.11.1.3. Growth in incidence of bleeding disorders
3.11.2. Restraints
3.11.2.1. Stringent government regulations
3.11.2.2. High cost of therapy
3.11.3. Opportunities
3.11.3.1. Opportunities in emerging economies
3.11.3.2. Development of cost-effective therapeutics through large-scale production
CHAPTER 4: IMMUNOGLOBULIN MARKET, BY APPLICATION
4.1. Overview
4.1.1. Market size and forecast
4.2. Hypogammaglobulinemia
4.2.1. Market size and forecast
4.3. Chronic Inflammatory demyelinating polyneuropathy (CIDP)
4.3.1. Market size and forecast
4.4. Primary immunodeficiency diseases
4.4.1. Market size and forecast
4.5. Myasthenia Gravis
4.5.1. Market size and forecast
4.6. Multifocal motor neuropathy
4.6.1. Market size and forecast
4.7. Idiopathic thrombocytopenic purpura (ITP)
4.7.1. Market size and forecast
4.8. Inflammatory myopathies
4.8.1. Market size and forecast
4.9. Specific antibody deficiency
4.9.1. Market size and forecast
4.10. Guillain-Barre syndrome
4.10.1. Market size and forecast
4.11. Others
4.11.1. Market size and forecast
CHAPTER 5: IMMUNOGLOBULIN MARKET, BY PRODUCT
5.1. Overview
5.1.1. IGG
5.1.1.1. Key market trends
5.1.2. Clinical interpretations
5.1.3. IGA
5.1.3.1. Key Market Trends
5.1.4. Clinical interpretation
5.1.5. IGM
5.1.5.1. Key Market Trends
5.1.6. Clinical interpretation
5.1.7. IGE
5.1.7.1. Key Market Trend
5.1.8. Clinical interpretation
5.1.9. IGD
5.1.9.1. Key Market Trends
5.1.10. Clinical interpretation
CHAPTER 6: INTRVAENOUS IMMUNOGLOBULIN MARKET, BY REGION
6.1. Overview
6.1.1. Market size and forecast
6.2. North America
6.2.1. Key trends and opportunities
6.2.2. North America market size & forecast, by application
6.2.3. North America market size & forecast, by country
6.2.3.1. U.S. market size & forecast
6.2.3.2. Canada market size & forecast
6.2.3.3. Mexico market size & forecast
6.3. Europe
6.3.1. Key trends and opportunities
6.3.2. Europe market size & forecast, by application
6.3.3. Europe market size & forecast for immunoglobulin market, by country
6.3.3.1. Germany market size & forecast
6.3.3.2. France market size & forecast
6.3.3.3. UK market size & forecast
6.3.3.4. Italy market size & forecast
6.3.3.5. Austria market size & forecast
6.3.3.6. Russia market size & forecast
6.3.3.7. Rest of Europe market size & forecast
6.4. Asia-Pacific
6.4.1. Key trends and opportunities
6.4.2. Asia-Pacific market size & forecast, by application
6.4.3. Asia-Pacific market size & forecast, by country
6.4.3.1. Australia market size & forecast
6.4.3.2. China market size & forecast
6.4.3.3. India market size & forecast
6.4.3.4. Japan market size & forecast
6.4.3.5. Rest of Asia-Pacific market size & forecast
6.5. LAMEA
6.5.1. Key trends and opportunities
6.5.2. LAMEA market size & forecast, by application
6.5.3. LAMEA market size & forecast, by country
6.5.3.1. Brazil market size & forecast
6.5.3.2. Saudi Arabia market size & forecast
6.5.3.3. Argentina market size & forecast
6.5.3.4. Turkey market size & forecast
6.5.3.5. Rest of LAMEA market size & forecast
CHAPTER 7: COMPANY PROFILES
7.1. BAXTER INTERNATIONAL INC.
7.1.1. Company overview
7.1.2. Company snapshot
7.1.3. Operating business segments
7.1.4. Product portfolio
7.1.5. Business performance
7.1.6. Key strategic moves and developments
7.2. BAYER AG
7.2.1. Company overview
7.2.2. Company snapshot
7.2.3. Operating business segments
7.2.4. Product portfolio
7.2.5. Business performance
7.2.6. Key strategic moves and developments
7.3. BIOTEST AG
7.3.1. Company overview
7.3.2. Company snapshot
7.3.3. Operating business segments
7.3.4. Product portfolio
7.3.5. Business performance
7.4. CHINA BIOLOGIC PRODUCTS, INC.
7.4.1. Company overview
7.4.2. Company snapshot
7.4.3. Operating business segments
7.4.4. Product portfolio
7.4.5. Business performance
7.5. CSL LIMITED
7.5.1. Company overview
7.5.2. Company snapshot
7.5.3. Operating business segments
7.5.4. Product portfolio
7.5.5. Business performance
7.6. GRIFOLS S.A.
7.6.1. Company overview
7.6.2. Company snapshot
7.6.3. Operating business segments
7.6.4. Product portfolio
7.6.5. Business performance
7.6.6. Key strategic moves and developments
7.7. KEDRION BIOPHARMA INC.
7.7.1. Company overview
7.7.2. Company snapshot
7.7.3. Operating business segments
7.7.4. Product portfolio
7.7.5. Business performance
7.7.6. Key strategic moves and developments
7.8. LFB SA (LFB BIOTECHNOLOGIES SAS)
7.8.1. Company overview
7.8.2. Company snapshot
7.8.3. Operating business segments
7.8.4. Product portfolio
7.8.5. Business performance
7.9. OCTAPHARMA AG
7.9.1. Company overview
7.9.2. Company snapshot
7.9.3. Operating business segments
7.9.4. Product portfolio
7.9.5. Business performance
7.10. TAKEDA PHARMACEUTICAL COMPANY LIMITED
7.10.1. Company overview
7.10.2. Company snapshot
7.10.3. Operating business segments
7.10.4. Product portfolio
7.10.5. Business performance
7.10.6. Key strategic moves and developments
LIST OF TABLES
TABLE 01. INDIA FLOOR COATING MARKET, BY BINDER TYPE, 2017-2025, ($THOUSAND)
TABLE 02. INDIA EPOXY FLOOR COATING MARKET, BY REGION, 2017-2025, ($THOUSAND)
TABLE 03. INDIA THERMOPLASTIC FLOOR COATING MARKET, BY REGION, 2017-2025, ($THOUSAND)
TABLE 04. INDIA THERMOSET FLOOR COATING MARKET, BY REGION, 2017-2025, ($THOUSAND)
TABLE 05. INDIA OTHER FLOOR COATING MARKET, BY REGION, 2017-2025, ($THOUSAND)
TABLE 06. INDIA FLOOR COATING MARKET, BY COATING COMPONENT, 2017-2025, ($THOUSAND)
TABLE 07. INDIA 1-K FLOOR COATING MARKET, BY REGION, 2017-2025, ($THOUSAND)
TABLE 08. INDIA 2-K FLOOR COATING MARKET, BY REGION, 2017-2025, ($THOUSAND)
TABLE 09. INDIA 3-K FLOOR COATING MARKET, BY REGION, 2017-2025, ($THOUSAND)
TABLE 10. INDIA FLOOR COATING MARKET, BY COATING COMPONENT, 2017-2025, ($THOUSAND)
TABLE 11. INDIA FLOOR COATINGS MARKET FOR WOODEN FLOORING, BY REGION, 2017-2025, ($THOUSAND)
TABLE 12. INDIA FLOOR COATINGS MARKET FOR TERRAZZO FLOORING, BY REGION, 2017-2025, ($THOUSAND)
TABLE 13. INDIA FLOOR COATINGS MARKET FOR MORTAR FLOORING, BY REGION, 2017-2025, ($THOUSAND)
TABLE 14. INDIA FLOOR COATINGS MARKET FOR OTHER FLOORING TYPES, BY REGION, 2017-2025, ($THOUSAND)
TABLE 15. INDIA FLOOR COATING MARKET, BY END USE, 2017-2025 ($THOUSAND)
TABLE 16. INDIA FLOOR COATING MARKET, BY RESIDENTIAL USE, 2017-2025, ($THOUSAND)
TABLE 17. INDIA FLOOR COATING MARKET FOR RESIDENTIAL, BY REGION, 2017-2025, ($THOUSAND)
TABLE 18. INDIA FLOOR COATING MARKET, BY COMMERCIAL USE, 2017-2025, ($THOUSAND)
TABLE 19. INDIA FLOOR COATING MARKET FOR COMMERCIAL, BY REGION, 2017-2025, ($THOUSAND)
TABLE 20. INDIA FLOOR COATING MARKET, BY INDUSTRIAL USE, 2017-2025, ($THOUSAND)
TABLE 21. INDIA FLOOR COATING MARKET FOR INDUSTRIAL, BY REGION, 2017-2025, ($THOUSAND)
TABLE 22. INDIA FLOOR COATINGS MARKET, BY REGION, 2017-2025 ($THOUSAND)
TABLE 23. NORTH INDIA FLOOR COATINGS MARKET, BY BINDER TYPE, 2017-2025 ($THOUSAND)
TABLE 24. NORTH INDIA FLOOR COATING MARKET, BY COATING COMPONENT, 2017-2025, ($THOUSAND)
TABLE 25. NORTH INDIA FLOOR COATING MARKET, BY FLOORING STRUCTURE, 2017-2025, ($THOUSAND)
TABLE 26. NORTH INDIA FLOOR COATINGS MARKET, BY END USE, 2017-2025 ($THOUSAND)
TABLE 27. NORTH INDIA FLOOR COATING MARKET, BY RESIDENTIAL USE, 2017-2025, ($THOUSAND)
TABLE 28. NORTH INDIA FLOOR COATING MARKET, BY COMMERCIAL USE, 2017-2025, ($THOUSAND)
TABLE 29. NORTH INDIA FLOOR COATING MARKET, BY INDUSTRIAL USE, 2017-2025, ($THOUSAND)
TABLE 30. EAST INDIA FLOOR COATINGS MARKET, BY BINDER TYPE, 2017-2025 ($THOUSAND)
TABLE 31. EAST INDIA FLOOR COATING MARKET, BY COATING COMPONENT, 2017-2025, ($THOUSAND)
TABLE 32. EAST INDIA FLOOR COATING MARKET, BY FLOORING STRUCTURE, 2017-2025, ($THOUSAND)
TABLE 33. EAST INDIA FLOOR COATINGS MARKET, BY END USE, 2017-2025 ($THOUSAND)
TABLE 34. EAST INDIA FLOOR COATING MARKET, BY RESIDENTIAL USE, 2017-2025, ($THOUSAND)
TABLE 35. EAST INDIA FLOOR COATING MARKET, BY COMMERCIAL USE, 2017-2025, ($THOUSAND)
TABLE 36. EAST INDIA FLOOR COATING MARKET, BY INDUSTRIAL USE, 2017-2025, ($THOUSAND)
TABLE 37. WEST INDIA FLOOR COATINGS MARKET, BY BINDERTYPE, 2017-2025($THOUSAND)
TABLE 38. WEST INDIA FLOOR COATING MARKET, BY COATING COMPONENT, 2017-2025, ($THOUSAND)
TABLE 39. WEST INDIA FLOOR COATING MARKET, BY FLOORING STRUCTURE, 2017-2025, ($THOUSAND)
TABLE 40. WEST INDIA FLOOR COATINGS MARKET, BY END USE, 2017-2025 ($THOUSAND)
TABLE 41. WEST INDIA FLOOR COATING MARKET, BY RESIDENTIAL USE, 2017-2025, ($THOUSAND)
TABLE 42. WEST INDIA FLOOR COATING MARKET, BY COMMERCIAL USE, 2017-2025, ($THOUSAND)
TABLE 43. WEST INDIA FLOOR COATING MARKET, BY INDUSTRIAL USE, 2017-2025, ($THOUSAND)
TABLE 44. SOUTH INDIA FLOOR COATINGS MARKET, BY BINDER TYPE, 2017-2025 ($THOUSAND)
TABLE 45. SOUTH INDIA FLOOR COATING MARKET, BY COATING COMPONENT, 2017-2025, ($THOUSAND)
TABLE 46. SOUTH INDIA FLOOR COATING MARKET, BY FLOORING STRUCTURE, 2017-2025, ($THOUSAND)
TABLE 47. SOUTH INDIA FLOOR COATINGS MARKET, BY END USE, 2017-2025 ($THOUSAND)
TABLE 48. SOUTH INDIA FLOOR COATING MARKET, BY RESIDENTIAL USE, 2017-2025, ($THOUSAND)
TABLE 49. SOUTH INDIA FLOOR COATING MARKET, BY COMMERCIAL USE, 2017-2025, ($THOUSAND)
TABLE 50. SOUTH INDIA FLOOR COATING MARKET, BY INDUSTRIAL USE, 2017-2025, ($THOUSAND)
TABLE 51. AKZO NOBEL N.V. (AKZO): COMPANY SNAPSHOT
TABLE 52. AKZO NOBEL N.V. (AKZO): OPERATING SEGMENTS
TABLE 53. AKZO NOBEL N.V. (AKZO): PRODUCT PORTFOLIO
TABLE 54. ARKEMA S.A.: COMPANY SNAPSHOT
TABLE 55. ARKEMA S.A.: OPERATING SEGMENTS
TABLE 56. ARKEMA S.A.: PRODUCT PORTFOLIO
TABLE 57. ASIAN PAINTS: COMPANY SNAPSHOT
TABLE 58. ASIAN PAINTS: OPERATING SEGMENTS
TABLE 59. ASIAN PAINTS: PRODUCT PORTFOLIO
TABLE 60. BERGER PAINTS: COMPANY SNAPSHOT
TABLE 61. BERGER PAINTS: OPERATING SEGMENTS
TABLE 62. BERGER PAINTS: PRODUCT PORTFOLIO
TABLE 63. DOWDUPONT: COMPANY SNAPSHOT
TABLE 64. DOWDUPONT: OPERATING SEGMENTS
TABLE 65. DOWDUPONT: PRODUCT PORTFOLIO
TABLE 66. FLOWCRETE GROUP: COMPANY SNAPSHOT
TABLE 67. FLOWCRETE GROUP: PRODUCT PORTFOLIO
TABLE 68. INDIGO PAINTS: COMPANY SNAPSHOT
TABLE 69. INDIGO PAINTS: PRODUCT PORTFOLIO
TABLE 70. KANSAI NEROLAC PAINTS: COMPANY SNAPSHOT
TABLE 71. KANSAI NEROLAC PAINTS: OPERATING SEGMENTS
TABLE 72. KANSAI NEROLAC PAINTS: PRODUCT PORTFOLIO
TABLE 73. SIKA AG: COMPANY SNAPSHOT
TABLE 74. SIKA AG: OPERATING SEGMENTS
TABLE 75. SIKA AG: PRODUCT PORTFOLIO
TABLE 76. 3M: COMPANY SNAPSHOT
TABLE 77. 3M: OPERATING SEGMENTS
TABLE 78. 3M: PRODUCT PORTFOLIO
LIST OF FIGURES
FIGURE 01. INTRAVENOUS IMMUNOGLOBULIN MARKET SEGMENTATION
FIGURE 02. TOP INVESTMENT POCKETS
FIGURE 03. LOW BARGAINING POWER OF SUPPLIERS
FIGURE 04. LOW BARGAINING POWER OF BUYERS
FIGURE 05. LOW THREAT OF SUBSTITUTION
FIGURE 06. LOW THREAT OF NEW ENTRANTS
FIGURE 07. MODERTAE COMPETITIVE RIVALRY
FIGURE 08. VALUE CHAIN ANALYSIS
FIGURE 09. MARKET SHARE ANALYSIS, 2017
FIGURE 10. GLOBAL IMMUNOGLOBULIN MARKET: DRIVERS, RESTRAINTS, AND OPPORTUNITIES
FIGURE 11. U.S. INTRAVENOUS IMMUNOGLOBULIN MARKET, VALUE ($MILLION) AND VOLUME (KILOGRAMS), 2017-2025
FIGURE 12. CANADA INTRAVENOUS IMMUNOGLOBULIN MARKET, VALUE ($MILLION) AND VOLUME (KILOGRAMS), 2017-2025
FIGURE 13. MEXICO INTRAVENOUS IMMUNOGLOBULIN MARKET, VALUE ($MILLION) AND VOLUME (KILOGRAMS), 2017-2025
FIGURE 14. GERMANY INTRAVENOUS IMMUNOGLOBULIN MARKET, VALUE ($MILLION) AND VOLUME (KILOGRAMS), 2017-2025
FIGURE 15. FRANCE INTRAVENOUS IMMUNOGLOBULIN MARKET, VALUE ($MILLION) AND VOLUME (KILOGRAMS), 2017-2025
FIGURE 16. UK INTRAVENOUS IMMUNOGLOBULIN MARKET, VALUE ($MILLION) AND VOLUME (KILOGRAMS), 2017-2025
FIGURE 17. ITALY INTRAVENOUS IMMUNOGLOBULIN MARKET, VALUE ($MILLION) AND VOLUME (KILOGRAMS), 2017-2025
FIGURE 18. AUSTRIA INTRAVENOUS IMMUNOGLOBULIN MARKET, VALUE ($MILLION) AND VOLUME (KILOGRAMS), 2017-2025
FIGURE 19. RUSSIA INTRAVENOUS IMMUNOGLOBULIN MARKET, VALUE ($MILLION) AND VOLUME (KILOGRAMS), 2017-2025
REST OF EUROPE INTRAVENOUS IMMUNOGLOBULIN MARKET, VALUE ($MILLION) AND VOLUME (KILOGRAMS), 2017-2025
FIGURE 20. AUSTRALIA INTRAVENOUS IMMUNOGLOBULIN MARKET, VALUE ($MILLION) AND VOLUME (KILOGRAMS), 2017-2025
FIGURE 21. CHINA INTRAVENOUS IMMUNOGLOBULIN MARKET, VALUE ($MILLION) AND VOLUME (KILOGRAMS), 2017-2025
FIGURE 22. INDIA INTRAVENOUS IMMUNOGLOBULIN MARKET, VALUE ($MILLION) AND VOLUME (KILOGRAMS), 2017-2025
FIGURE 23. JAPAN INTRAVENOUS IMMUNOGLOBULIN MARKET, VALUE ($MILLION) AND VOLUME (KILOGRAMS), 2017-2025
FIGURE 24. REST OF ASIA-PACIFIC INTRAVENOUS IMMUNOGLOBULIN MARKET, VALUE ($MILLION) AND VOLUME (KILOGRAMS), 2017-2025
FIGURE 25. BRAZIL INTRAVENOUS IMMUNOGLOBULIN MARKET, VALUE ($MILLION) AND VOLUME (KILOGRAMS), 2017-2025
FIGURE 26. SAUDI ARABIA INTRAVENOUS IMMUNOGLOBULIN MARKET, VALUE ($MILLION) AND VOLUME (KILOGRAMS), 2017-2025
FIGURE 27. ARGENTINA INTRAVENOUS IMMUNOGLOBULIN MARKET, VALUE ($MILLION) AND VOLUME (KILOGRAMS), 2017-2025
FIGURE 28. TURKEY INTRAVENOUS IMMUNOGLOBULIN MARKET, VALUE ($MILLION) AND VOLUME (KILOGRAMS), 2017-2025
FIGURE 29. REST OF LAMEA INTRAVENOUS IMMUNOGLOBULIN MARKET, VALUE ($MILLION) AND VOLUME (KILOGRAMS), 2017-2025
FIGURE 30. BAXTER: NET SALES, 20152017 ($MILLION)
FIGURE 31. BAXTER: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 32. BAYER: NET SALES, 20152017 ($MILLION)
FIGURE 33. BAYER: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 34. BAYER: REVENUE SHARE BY REGION, 2017 (%)
FIGURE 35. BIOTEST: NET SALES, 20152017 ($MILLION)
FIGURE 36. BIOTEST: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 37. BIOTEST: REVENUE SHARE BY REGION, 2017 (%)
FIGURE 38. CHINA BIOLOGIC NET SALES, 20152017 ($MILLION)
FIGURE 39. CSL: NET SALES, 20152017 ($MILLION)
FIGURE 40. CSL: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 41. CSL: REVENUE SHARE BY REGION, 2017 (%)
FIGURE 42. GRIFOLS: NET SALES, 20152017 ($MILLION)
FIGURE 43. GRIFOLS: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 44. GRIFOLS: REVENUE SHARE BY REGION, 2017 (%)
FIGURE 45. KEDRION: NET SALES, 20152017 ($MILLION)
FIGURE 46. KEDRION: REVENUE SHARE BY REGION, 2017 (%)
FIGURE 47. LFB: NET SALES, 20142016 ($MILLION)
FIGURE 48. LFB: REVENUE SHARE BY PRODUCT SEGMENT, 2016 (%)
FIGURE 49. LFB: REVENUE SHARE BY REGION, 2016 (%)
FIGURE 50. OCTAPHARMA: NET SALES, 20152017 ($MILLION)
FIGURE 51. TAKEDA: NET SALES, 20152017 ($MILLION)
FIGURE 52. TAKEDA: REVENUE SHARE BY REGION, 2017 (%)

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook